-
MyChart
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
- Donate Today
FDA approves ponatinib, third drug in four months; all clinical trials led by MD Anderson
MD Anderson News Release 12/21/12
The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+ALL). It approved the drug ponatinib (Iclusig), which is effective in a...
Phase 2 clinical trial shows high overall response, remissions in patients with resistant disease
MD Anderson News Release...
UT MD Anderson experts launch cancer prevention nutrition challenge
MD Anderson News Release 12/13/12
Adults with...
Platelets, white blood cells engraft more quickly than in standard double-cord transplant
MD Anderson News Release 12/12/12
Donated umbilical cord blood establishes a new blood supply in patients more quickly after transplantation when it is first expanded in the lab on a bed of cells that mimics conditions in the bone marrow, researchers report in the Dec. 13 edition of the New England Journal of Medicine.<...
Stand Up to Cancer and the Cancer Research Institute fund joint effort for next generation cancer immunology research
MD...
MD Anderson News Release 12/10/12
A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant...
Ibrutinib, rituximab deliver a one-two punch to patients with few good options
MD Anderson News Release 12/08/12
<...Deal to develop MD Anderson discovery draws on expertise of Institute for Applied Cancer Science
MD Anderson News Release...
Early results show benefit in most dangerous form of disease
MD Anderson News Release 12/06/12
Researchers from...
Older technique associated with higher rate of lymphedema, poor outcome
MD Anderson News Release 12/05/12
African...